Gansu Shangfeng Cement (000672.SZ) subsidiary Guangdong Xin Semiconductor's application for an IPO on the ChiNext board has been accepted.
Shangfeng Cement (000672.SZ) announced recently that its wholly-owned subsidiary Ningbo Shangrong Logistics Co., Ltd. has jointly established private equity investment funds with professional institutions as investment subjects - Shanghai Xinpuran Entrepreneurship Investment Partnership (Limited Partnership), Suzhou Jingpu Entrepreneurship Investment Partnership (Limited Partnership), and Suzhou Industrial Park Chuxin Entrepreneurship Investment Partnership (Limited Partnership), investing in the initial public offering and listing application of Guangdong Xin Semiconductor Technology Co., Ltd. (referred to as "Guangdong Xin Semiconductor") on the Growth Enterprise Market on December 19, 2025. Through consolidation and calculation, the company indirectly holds approximately 1.4957% of Guangdong Xin Semiconductor before its initial public offering and listing.
Gansu Shangfeng Cement (000672.SZ) announced that it recently learned that the company's wholly-owned subsidiary Ningbo Shangrong Logistics Co., Ltd. has invested in private equity investment funds jointly established with professional institutions as the investing entities. These funds are Shanghai Xinpu Ranyi Entrepreneurship Investment Partnership Enterprise (Limited Partnership), Suzhou Jingpu Entrepreneurship Investment Partnership Enterprise (Limited Partnership), and Suzhou Industrial Park Chuxin Entrepreneurship Investment Partnership Enterprise (Limited Partnership). They have invested in the initial public offering of Guangdong Xin Semiconductor Technology Co., Ltd. (referred to as "Guangdong Xin Semiconductor") and applied for listing on the Growth Enterprise Market on December 19, 2025, which was accepted by the Shenzhen Stock Exchange. After consolidation, Gansu Shangfeng Cement indirectly owns approximately 1.4957% equity in Guangdong Xin Semiconductor before its initial public offering.
Related Articles
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
SUNSHINE OIL (02012) plans to discount about 10% of the rights issue, raising a maximum of approximately 40.31 million Hong Kong dollars net.
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
SUNSHINE OIL (02012) plans to discount about 10% of the rights issue, raising a maximum of approximately 40.31 million Hong Kong dollars net.
